INTRODUCTION
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation, that tends to present as a lifelong condition with different severity degrees1. More than 315 million people are affected by asthma all over the world1; in Italy the prevalence of asthma is about 6.6%2. House Dust Mites (HDM) are one of the most common aeroallergens worldwide and up to 85% of asthmatics are typically HDM allergic3. More than 60% of asthmatics also have allergic rhinitis as co-morbidity4. The aim of this research was to investigate the Italian clinical pathway and the economic burden of disease for patients with allergic asthma, at different stages of severity.
METHODS
A retrospective Real-World Analysis was developed in Italy to evaluate the healthcare resources consumed for the management of patients with allergic asthma. Data were related to patients aged > 12 years with allergic asthma diagnosed by physician, treated between January 2015 and December 2016. Data were collected in aggregated and anonymous form, through the collaboration of four respiratory Centers of Excellence (CoEs). Patients were clustered by age (12-17, 18-65, >65 years) and grouped for disease severity according to the Global Initiative for Asthma (GINA) classification (Step 1 to Step 5). Overall costs were calculated by adding up drugs (i.e. ICS, LABA, LAMA, anti-IgE), diagnosis and visits costs, derived from real life data. 
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RESULTS
The study analysed records from 3.015 patients and most of them (2.160 patients) were 18-65 years old and were classified in Step GINA 3 and 4. Around 50% of all patients had HDM allergy and the most common comorbidity was allergic rhinitis (77%), step up (Table 1 ). The total expenditure for the management of allergic asthma was measured during twenty-four months. The analysis showed that the drug costs increased according to the degree of asthma severity, due to polytherapy and, in particular, to the use of a few high cost drugs (i.e anti-IgE) in Step 3 to
Step 5 ( Table 2 ). The patient clinical pathway included medical examination with pulmonologist, diagnostic exams and laboratory tests. Medical examination represented the major cost driver (Table 3) , owing to the routine follow-up (from 1 to 3 visits/year). Finally, the higher cost per patient was represented by drug for each cluster € 1.215 (12-17 y), € 735 (18-65 y) and € 632 (>65 y) (Figure 1 ). 
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